M2S Acquires DXA Resource Group
M2S, a global provider of image management services for biopharmaceutical and medical device clinical trials, announced today that the company has acquired DXA Resource Group (DRG) of Westborough, Mass.
M2S Acquires DXA Resource Group
M2S Inc., a global provider of image management services for biopharmaceutical and medical device clinical trials, announced today that the company has acquired DXA Resource Group (DRG) of Westborough, Mass.
Founded in 2002, DRG recognized the need for cost-effective and responsive DXA (Dual- Emission X-Ray Absorptiometry) clinical quality assurance], project management and data management services to support drug development. DXA, a low-dose (1/10th of traditional x-ray) imaging modality that measures bone mineral density and body mass composition, is increasingly utilized in clinical trials to assess the safety and effectiveness of drugs under development for indications such as osteoporosis, HIV, obesity, growth hormone deficiency, endometriosis, fibroids and Gaucher’s disease.
“DRG has integrated quality service with imaging data technology, which exactly fits into the M2S mission and clinical trials image management service offering. The addition of DRG allows M2S to further expand our capabilities and therapeutic expertise, and meet the growing demand for image management services worldwide,” M2S CEO Wes Chapman said.
“Adding M2S high-speed image collection and trial management technologies to DRG’s proprietary quality system and data management, enables us to greatly increase our presence in the drug development market,” said Reta Rupich, President of DXA Resource Group.
About M2S, Inc.
M2S provides image and data management services for clinical trials sponsors in the biopharmaceutical and medical device industries, patient registry databases and is a recognized leader in 3-D endovascular treatment planning. For the past 10 years, M2S has managed, under protocol, millions of images from around the globe in various therapeutic areas and in all DICOM modalities. For more information, visit www.m2s.com.
About DXA Resource Group
DXA Resource group is a clinical trials service company focused on providing customer-centric, cost-effective quality assurance as well as data and project management for clinical trials involving Dual X-ray Absorptiometry (DXA) measurements. For more information visit www.dxaresourcegroup.com or www.m2s.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
